Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study

Patient number Age Gender Race Comorbidities Duration of CRVO (months) Previous anti-VEGF agent # of injections Previous CME free interval (days) BCVA Central retinal thickness (µm) Total macular volume (mm3)
001 75 F White HTN 12.7 Ranibizumab 10 35 20/32 303 8.89
002 86 M White HTN 45.5 Bevacizumab 34 35 20/50 336 8.84
003 70 M White DM & HTN 13.2 Ranibizumab 10 37 20/32 458 9.3
004 38 F Hispanic None 10.5 Ranibizumab 8 42 20/50 269 8.05
005 73 M White HTN 22.1 Ranibizumab 14 45 20/32 283 7.34
006 92 F White HTN 17.8 Ranibizumab 9 56 20/80 485 8.67
007 82 M White HTN 10.9 Ranibizumab 9 28 20/32 482 10.63
008 81 M Asian None 15.7 Ranibizumab 11 42 20/25 282 8.98
009 85 F Hispanic HTN 8.5 Ranibizumab 7 42 20/200 591 11.43
010 71 F White None 58.1 Bevacizumab 47 35 20/40 355 7.96
011 70 M Hispanic HTN 89.8 Bevacizumab 37 42 20/250 736 14.1
012 87 F Hispanic HTN 10.2 Ranibizumab 7 42 20/160 450 9.16
013 65 F Hispanic None 7.7 Bevacizumab 6 35 20/25 344 9.59
014 78 F White HTN 7.8 Ranibizumab 6 56 20/50 302 8.49
015 61 M White None 8.5 Ranibizumab 6 35 20/125 512 9.75
016 81 F Hispanic HTN 20.0 Bevacizumab 12 42 20/25 538 8.37
017 51 M White HTN 6.4 Bevacizumab 6 28 20/25 355 9.16
018 68 F White DM & HTN 31.5 Ranibizumab 18 28 20/200 772 11.7
019 55 M Asian None 8.5 Ranibizumab 6 35 20/32 279 8.53
020 78 M White HTN 30.4 Bevacizumab 31 28 20/200 559 13.56
  1. VEGF vascular endothelial growth factor, CME cystoid macular edema, HTN hypertension, DM diabetes mellitus